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Abstract
Recent studies have described the spontaneous development of arthritis or vasculitis in IL-1
receptor antagonist (IL-1Ra) knockout mice bred on specific and different genetic
backgrounds. The levels of both secreted and intracellular isoforms of IL-1Ra produced in
the rheumatoid joint or in the arterial wall may not be adequate to effectively inhibit the
excess amounts of locally produced IL-1. Thus, an imbalance between IL-1 and IL-1Ra may
predispose to local inflammatory disease in particular tissues in the presence of other as yet
unknown genetically influenced factors.
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CIA = collagen-induced arthritis; icIL-1Ra = intracellular IL-1 receptor antagonist; IL-1Ra = IL-1 receptor antagonist; GCA = giant cell arteritis; 
PAN = polyarteritis nodosa; RA = rheumatoid arthritis; sIL-1Ra = secretory IL-1 receptor antagonist; TGF = transforming growth factor; TNF =
tumor necrosis factor.
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Introduction
The IL-1 family includes two agonists, IL-1a and IL-1b,
and a naturally occurring receptor antagonist, IL-1Ra.
IL-1Ra is produced locally in various tissues in response
to infection or inflammation, and is present in high levels
in the circulation secondary to hepatic production as an
acute-phase protein [1]. Multiple isoforms of IL-1Ra have
been described: a 17-kDa form secreted from monocytes
and other cells as variably glycosylated proteins of
22–25kDa, and at least three intracellular molecules
[2,3]. The first described intracellular isoform of IL-1Ra
(icIL-1Ra1) predominates in epithelial cells and fibrob-
lasts, and is a delayed product of transcription in mono-
cytes. The role in physiology of secretory IL-1Ra (sIL-1Ra)
appears to be to inhibit competitively the local inflamma-
tory effects of IL-1. Although icIL-1Ra isoforms may be
released from dying cells and may also function as recep-
tor blockers, other possible functions of icIL-1Ra isoforms
inside cells may exist [3].
The results of two recent studies of IL-1Ra knockout mice
[4,5] further the hypothesis that maintenance of a balance
between IL-1 and IL-1Ra may be important in preventing the
development of inflammatory diseases. Horai et al [4]
described the spontaneous development of inflammatory
arthritis in IL-1Ra knockout mice bred on the BALB/cA
background, with many features resembling rheumatoid
arthritis (RA) in humans. In contrast, an arterial inflammatory
disease resembling polyarteritis nodosa (PAN) sponta-
neously developed in IL-1Ra knockout mice bred on a
MFI×129 background [5]. These fascinating observations
pose questions about the possible pathophysiologic conse-
quences of an imbalance between IL-1 and IL-1Ra in inflam-
matory disease in the joints or vessel walls in humans.Arthritis Research    Vol 2 No 4 Arend and Gabay
Interleukin-1 and its receptor antagonist in
inflammatory arthritis
The role of cytokines in RA, and the rationale for inhibition
of IL-1 and tumor necrosis factor (TNF)-a in this disease
have been extensively reviewed [6,7]. Much evidence indi-
cates that both of these proinflammatory cytokines are
overproduced in the rheumatoid joint and are key media-
tors in both inflammation and tissue destruction. The
demonstrated success of the therapeutic administration of
inhibitors of IL-1 and TNF-a offers further support for the
importance of these cytokines in the rheumatoid disease
process. However, much less is known about the impor-
tance and role of natural mechanisms to counteract the
effects of IL-1 and TNF-a in the joint, and whether an
imbalance in these mechanisms may predispose to the
development of RA. Endogenous inhibitors of IL-1 and
TNF-a include their respective soluble receptors; IL-1
effects may be further blocked by IL-1Ra.
The results of studies in animal models of arthritis suggest
an important anti-inflammatory role for endogenous
IL-1Ra. Lipopolysaccharide-induced arthritis in rabbits
markedly worsened after administration of a neutralizing
antibody to IL-1Ra [8]. Furthermore, arthritis in numerous
animal models was significantly ameliorated after treat-
ment with IL-1Ra, suggesting that the level of production
of endogeneous IL-1Ra was inadequate to counteract the
effects of local IL-1 fully [3]. Collagen-induced arthritis
(CIA) exhibited an earlier onset and more severe course in
mice rendered genetically deficient in production of all iso-
forms of IL-1Ra, whereas the opposite pattern was
observed in mice transgenic for sIL-1Ra [9]. Studies on
the temporal production of various cytokines in CIA indi-
cated that peak IL-1b mRNA levels in synovial tissue were
observed within the first week after the onset of arthritis,
whereas levels of IL-1Ra mRNA continued to rise for
weeks later [10]. Recent work in our laboratory (Gabay C
et al, unpublished data) demonstrated that the mRNA for
both sIL-1Ra and icIL-1Ra1 were found in the inflamed
synovium after the second week of CIA, paralleling the
resolution of acute arthritis. The amounts of IL-1b mRNA
decreased after day 15, with the cytokine balance being in
favor of IL-1Ra. These observations suggest that both sIL-
1Ra and icIL-1Ra1 may play important anti-inflammatory
roles in CIA in mice.
Rheumatoid synovitis also demonstrates an imbalance
between production of IL-1a and IL-1Ra. Immunohistologic
studies [11] indicated that IL-1 was present in approxi-
mately 90% of cells at the cartilage–pannus junction,
whereas staining for IL-1Ra was found in less than 10% of
the cells. In addition, chondrocytes in the articular carti-
lage near the pannus contained IL-1a in four out of five RA
samples, with approximately 65% of the cells containing
IL-1a, whereas IL-1Ra was detected in only one sample,
with less than 10% of the cells being positive. IL-1Ra was
produced primarily by macrophages in the rheumatoid
synovium, with little protein found in fibroblasts [12,13].
The amounts of IL-1Ra produced by cultured rheumatoid
synovial tissue were inadequate to inhibit the amounts of
IL-1 produced by the same tissue effectively [14,15].
Finally, in recent studies we failed to detect icIL-1Ra1
mRNA or protein in 10 synovectomy samples from eight
patients with active RA of long duration, whereas sIL-1Ra
mRNA and protein were present in all samples (unpub-
lished observations).
Thus, it appears that endogenous IL-1Ra is certainly anti-
inflammatory, but may not reach high enough local levels
of production to inhibit early synovitis effectively. Our
recent studies (Gabay C et al, unpublished data) on CIA
in mice suggest that delayed production of icIL-1Ra1 by
synovial fibroblasts and macrophages may contribute to
resolution of the acute synovitis. An absence or deficiency
in synovial cell production of icIL-1Ra1 in some RA
patients may predispose to continued active synovitis.
The recent observation of spontaneous development of
inflammatory arthritis in IL-1Ra knockout mice further sup-
ports the hypothesis that a balance between IL-1 and
IL-1Ra is important for maintenance of homeostasis and
prevention of disease. Although the absence of IL-1Ra did
not affect T-cell and B-cell numbers, the IL-1Ra knockout
mice developed autoantibodies such as rheumatoid
factors, antibodies to double-stranded DNA, and antibod-
ies to collagen type II [4]. Both IL-1a and IL-1b were con-
stitutively present in normal mouse joints. However, the
expression of IL-1b mRNA was elevated twofold to three-
fold in the joints of IL-1Ra knockout mice before the onset
of arthritis, and mRNA for IL-1b, IL-6, and TNF-a were all
elevated in the synovium of mice during active arthritis.
This finding suggests that the absence of IL-1Ra predis-
poses to an augmented local production, as well as effect,
of proinflammatory cytokines. However, it seems unlikely
that arthritis developed spontaneously just because of
unopposed activity of the low levels of basal IL-1Ra; other
as yet unknown pathophysiologic factors must have been
operative as well. Without these other factors, possibly
enhancing local IL-1 production, an absence of IL-1Ra
may not have been deleterious.
A further analysis of the genetic influences in this model
may establish additional mechanisms that, in the presence
of an imbalance in the IL-1 system, predispose to arthritis.
Early spontaneous development of arthritis was observed
only in IL-1Ra knockout mice bred on the BALB/cA back-
ground, but not on the C57BL/6J background [4].
However, IL-1Ra knockout mice of the C57BL/6J back-
ground developed a high incidence of arthritis after immu-
nization with collagen type II, and knockout mice bred on
the DBA/1 background developed more severe CIA than
IL-1Ra-producing mice. These findings may indicate thathttp://arthritis-research.com/content/2/4/245
the anti-inflammatory effects of endogenous IL-1Ra are
important in any animal model of arthritis, or that the
absence of IL-1Ra may have altered the immune response.
Finally, in light of the arguments offered above, it would be
of interest to examine whether absence of production of
icIL-1Ra1 alone, and not also of sIL-1Ra, would similarly
predispose to or worsen arthritis in animal models.
Interleukin-1 and its receptor antagonist in
inflammatory vascular disease
In comparison with arthritis, a less firm scientific founda-
tion exists to support the possible involvement of IL-1 and
IL-1Ra in inflammatory vascular disease. However, inflam-
mation is thought to be an important component in athero-
sclerotic vascular disease after mechanical damage to
endothelial cells in the intima. Stimulation of foam cells in
atheromatous lesions by oxidized lipoproteins is thought to
be the responsible mechanism for enhanced local produc-
tion of IL-1 [16,17]. In turn, IL-1 leads to the production of
platelet-derived growth factor, which may stimulate
smooth muscle cells and fibroblasts into further participa-
tion in pathologic events in the vessel wall.
IL-1Ra was detected in the endothelium of diseased coro-
nary arteries [17], and administration of IL-1Ra inhibited
fatty streak formation in the apolipoprotein E knockout
mouse [18]. Cultured human umbilical vein endothelial
cells stimulated by a variety of conditions were not
observed to produce IL-1Ra mRNA or protein in two
earlier studies [19,20]. However, in recent studies [21]
human umbilical vein endothelial cells stimulated by
lipopolysaccharide, phorbol myristate acetate or trans-
forming growth factor (TGF)-b produced icIL-1Ra1
mRNA, and atherosclerotic coronary arteries contained
mRNA for both IL-1Ra isoforms, as determined by reverse
transcription polymerase chain reaction. Thus, IL-1Ra
found in the vessel wall during inflammatory conditions
may be derived from infiltrating macrophages or myoep-
ithelial cells, or possibly from endothelial cells, with icIL-
1Ra1 possibly being the major isoform produced.
However, the results of studies in animal models of athero-
sclerosis and in patients with coronary artery disease
would suggest that the levels of endogenous production
of IL-1Ra in the vessel wall may not be sufficient to inhibit
the effects of IL-1 produced locally.
The presence of IL-1 in the vessel wall in forms of vasculi-
tis in humans has been examined only in giant cell arteritis
(GCA). Temporal artery biopsy specimens from patients
with GCA contained mRNA for the macrophage cytokines
IL-1b, IL-6, and TGF-b1, as well as for the T-cell cytokines
IFN-g and IL-2, as determined by reverse transcription
polymerase chain reaction [22]. The IL-1b, IL-6, and TGF-
b proteins were localized by immunohistochemistry primar-
ily to CD68+ macrophages in the adventitia, in the vicinity
of activated CD4+ T cells producing IFN-g [23]. The IFN-g-
producing CD4+ T cells in the adventitia of temporal artery
biopsies in GCA were CD45RO-positive, suggesting a
memory phenotype, and a subset of these cells exhibited
markers of proliferation [24]. IL-1Ra mRNA or proteins
were not examined in these studies.
These findings imply that GCA is mediated by T cells in
the adventitia responding to unknown endogenous or
exogenous antigens, then activating nearby macrophages
to secrete cytokines including IL-1b, leading through
unclear mechanisms to eventual damage to the inner
media and intima [24]. The possibility exists that the local
production of IL-1Ra may be inadequate to oppose the
IL-1 effects. Histologic studies on small and medium-sized
arteries in nerve and muscle biopsies from patients with
PAN [25] indicated a similar predominance of
macrophages and CD4+ T cells, although the presence of
cytokines in these inflamed vessels was not determined.
The implication is that PAN may also be a T-cell-mediated
disease, however, involving effector macrophages and
possibly local cytokine production.
The spontaneous arteritis described in IL-1Ra knockout
mice bred on the MFI×129 background developed at
points in the vasculature subjected to high turbulence or
stress, similar to the pattern of lesions in atherosclerosis
or PAN, but different from GCA [5]. Homozygous animals
died prematurely from consequences of the inflammatory
vasculitis, whereas heterozygotes developed small lesions
that were not usually fatal. This observation suggests that,
in the presence of a partial deficiency in IL-1Ra, the vessel
wall is able to heal or contain the lesion. IL-1b was demon-
strated in the vessel wall lesions, localized primarily to
macrophages often found in association with CD4+
T cells. However, whether IL-1b was present in uninvolved
segments of the vessel wall was not examined in these
studies. Arteritis has not been found in IL-1Ra knockout
mice bred on other genetic backgrounds.
Thus, the description of spontaneous arteritis in IL-1Ra
knockout mice suggests that expression of IL-1Ra in the
vessel wall, or in the circulation, may be necessary to
counteract the potentially injurious effects of local IL-1
production, possibly induced by mechanical damage to
the endothelium. Determination of the genetic influences
on the development of arteritis in this model, which are
acting in combination with a lack of IL-1Ra, may indicate
possible predisposing factors in patients with PAN.
Conclusion
An imbalance between IL-1 and IL-1Ra may predispose to
inflammatory arthritis and arteritis, in the presence of other
as yet unknown genetically influenced factors. Thus,
endogenous IL-1Ra may serve an important role in pre-
venting or limiting organ damage under local conditions,
leading to excess IL-1 production. Possibly sIL-1Ra, eitherpresent in the circulation as a product of hepatocytes, or
produced locally from tissue macrophages, may serve a
necessary regulatory function. Alternatively, icIL-1Ra1 pro-
duction by fibroblasts, macrophages, endothelial cells, or
cells of epithelial origin may restore the local cytokine
balance in diseased organs. A deeper understanding of
the presence and regulation of production of IL-1Ra iso-
forms, and of their biologic effects on or in specific cells or
tissues, may clarify whether a relative imbalance between
IL-1 and IL-1Ra plays an important predisposing role in
acute and chronic inflammatory diseases in humans.
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